Essential biphasic role for JAK3 catalytic activity in IL-2 receptor signaling

Nature Chemical Biology

Volumn 12, Issue 5, 2016, Pages 373-379

  Smith, Geoffrey A ^a   Uchida, Kenji ^a,c   Weiss, Arthur ^a,b   Taunton, Jack ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CYCLINE; FC RECEPTOR; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; JANUS KINASE 3; MESSENGER RNA; MUTANT PROTEIN; STAT5 PROTEIN; GAMMA INTERFERON; JAK3 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CD4+ T LYMPHOCYTE; CELL CYCLE S PHASE; CONTROLLED STUDY; ENZYME MECHANISM; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ANIMAL; APOPTOSIS; C57BL MOUSE; CELL CULTURE; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; PHYSIOLOGY; SITE DIRECTED MUTAGENESIS;

ANIMALS; APOPTOSIS; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; FEMALE; GENE EXPRESSION REGULATION; INTERFERON-GAMMA; INTERLEUKIN-2; JANUS KINASE 3; MALE; MICE; MICE, INBRED C57BL; MUTAGENESIS, SITE-DIRECTED; RECEPTORS, INTERLEUKIN-2; SIGNAL TRANSDUCTION;

EID: 84961722011     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.2056     Document Type: Article

References (35)

1. Rochman, Y., Spolski, R. & Leonard, W.J. New insights into the regulation of T cells by γ(c) family cytokines. Nat. Rev. Immunol. 9, 480-490 (2009).
2. Miyazaki, T. et al. Functional activation of Jak1 and Jak3 by selective association with IL-2 receptor subunits. Science 266, 1045-1047 (1994).
3. Ghoreschi, K., Laurence, A. & O'Shea, J.J. Janus kinases in immune cell signaling. Immunol. Rev. 228, 273-287 (2009).
4. Liao, W., Lin, J.-X. & Leonard, W.J. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity 38, 13-25 (2013).
5. Lin, J.-X. et al. Critical Role of STAT5 transcription factor tetramerization for cytokine responses and normal immune function. Immunity 36, 586-599 (2012).
6. Laurence, A. et al. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity 26, 371-381 (2007).
7. Lockyer, H.M., Tran, E. & Nelson, B.H. STAT5 is essential for Akt/p70S6 kinase activity during IL-2-induced lymphocyte proliferation. J. Immunol. 179, 5301-5308 (2007).
8. Yao, Z. et al. Stat5a/b are essential for normal lymphoid development and differentiation. Proc. Natl. Acad. Sci. USA 103, 1000-1005 (2006).
9. Thomis, D.C., Gurniak, C.B., Tivol, E., Sharpe, A.H. & Berg, L.J. Defects in B lymphocyte maturation and T lymphocyte activation in mice lacking Jak3. Science 270, 794-797 (1995).
10. Thomis, D.C. & Berg, L.J. Peripheral expression of Jak3 is required to maintain T lymphocyte function. J. Exp. Med. 185, 197-206 (1997).
11. Witthuhn, B.A., Williams, M.D., Kerawalla, H. & Uckun, F.M. Differential substrate recognition capabilities of Janus family protein tyrosine kinases within the interleukin 2 receptor (IL2R) system: Jak3 as a potential molecular target for treatment of leukemias with a hyperactive Jak-Stat signaling machinery. Leuk. Lymphoma 32, 289-297 (1999).
12. Haan, C. et al. Jak1 has a dominant role over Jak3 in signal transduction through γc-containing cytokine receptors. Chem. Biol. 18, 314-323 (2011).
13. Perona-Wright, G., Mohrs, K. & Mohrs, M. Sustained signaling by canonical helper T cell cytokines throughout the reactive lymph node. Nat. Immunol. 11, 520-526 (2010).
14. Swainson, L. et al. IL-7-induced proliferation of recent thymic emigrants requires activation of the PI3K pathway. Blood 109, 1034-1042 (2007).
15. Liao, W. et al. Opposing actions of IL-2 and IL-21 on Th9 differentiation correlate with their differential regulation of BCL6 expression. Proc. Natl. Acad. Sci. USA 111, 3508-3513 (2014).
16. Arneja, A., Johnson, H., Gabrovsek, L., Lauffenburger, D.A. & White, F.M. Qualitatively different T cell phenotypic responses to IL-2 versus IL-15 are unified by identical dependences on receptor signal strength and duration. J. Immunol. 192, 123-135 (2014).
17. Cantrell, D.A. & Smith, K.A. The interleukin-2 T-cell system: a new cell growth model. Science 224, 1312-1316 (1984).
18. London, N. et al. Covalent docking of large libraries for the discovery of chemical probes. Nat. Chem. Biol. 10, 1066-1072 (2014).
19. Goedken, E.R. et al. Tricyclic covalent inhibitors selectively target Jak3 through an active site thiol. J. Biol. Chem. 290, 4573-4589 (2015).
20. Tan, L. et al. Development of selective covalent Janus kinase 3 inhibitors. J. Med. Chem. 58, 6589-6606 (2015).
21. Clark, J.D., Flanagan, M.E. & Telliez, J.-B. Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. J. Med. Chem. 57, 5023-5038 (2014).
22. Readinger, J.A., Mueller, K.L., Venegas, A.M., Horai, R. & Schwartzberg, P.L. Tec kinases regulate T-lymphocyte development and function: new insights into the roles of Itk and Rlk/Txk. Immunol. Rev. 228, 93-114 (2009).
23. Ahearn, S.P. et al. Pyrrolopyrimidines as Janus kinase inhibitors. WIPO patent WO085802A1 (2013).
24. Brennan, P. et al. Phosphatidylinositol 3-kinase couples the interleukin-2 receptor to the cell cycle regulator E2F. Immunity 7, 679-689 (1997).
25. Cornish, G.H., Sinclair, L.V. & Cantrell, D.A. Differential regulation of T-cell growth by IL-2 and IL-15. Blood 108, 600-608 (2006).
26. Schaeffer, E.M. et al. Requirement for Tec kinases Rlk and Itk in T cell receptor signaling and immunity. Science 284, 638-641 (1999).
27. Rowell, E.A. & Wells, A.D. The role of cyclin-dependent kinases in T-cell development, proliferation, and function. Crit. Rev. Immunol. 26, 189-212 (2006).
28. Wormald, S. et al. The comparative roles of suppressor of cytokine signaling-1 and-3 in the inhibition and desensitization of cytokine signaling. J. Biol. Chem. 281, 11135-11143 (2006).
29. Cornish, A.L. et al. Suppressor of cytokine signaling-1 regulates signaling in response to interleukin-2 and other γ c-dependent cytokines in peripheral T cells. J. Biol. Chem. 278, 22755-22761 (2003).
30. Yang, X.O. et al. The signaling suppressor CIS controls proallergic T cell development and allergic airway inflammation. Nat. Immunol. 14, 732-740 (2013).
31. Babon, J.J. et al. Suppression of cytokine signaling by SOCS3: characterization of the mode of inhibition and the basis of its specificity. Immunity 36, 239-250 (2012).
32. Dowty, M.E. et al. Preclinical to clinical translation of tofacitinib, a Janus kinase inhibitor, in rheumatoid arthritis. J. Pharmacol. Exp. Ther. 348, 165-173 (2014).
33. Xing, L. et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat. Med. 20, 1043-1049 (2014).
34. Ghoreschi, K. et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J. Immunol. 186, 4234-4243 (2011).
35. Krutzik, P.O. & Nolan, G.P. Fluorescent cell barcoding in flow cytometry allows high-throughput drug screening and signaling profiling. Nat. Methods 3, 361-368 (2006).